Rain Therapeutics raised $18.4 million in series A funding, which will advance its lead program, a hypoxia-activated prodrug, in a population of patients with non-small cell lung cancer for whom there are no treatments.
Rain Therapeutics nets $18M to push lung cancer asset into phase 2 Read More »
We spoke to Nassim Usman, CEO of Catalyst, about the company’s approach to hemophilia, how its drugs work, and why he believes his company’s pipeline may provide better alternatives for hemophilia patients.
The Case for a Daily Self-Injection to Treat Hemophilia Read More »
The clinical-stage biotech has diverse pipeline generated by its Wnt signalling pathway technology platform, and aims to get its first drug to market in 2020.
Samumed CMO Hopes To Reach Drug Approvals Via The Wnt Pathway Read More »
Celyad has reported clinical results showing the first time a patient has fully recovered from acute myeloid leukemia thanks to a CAR-T therapy, and without the need for chemotherapy preconditioning.
“This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukemia“ Read More »
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it will divest its rare disease gene therapy portfolio, including Strimvelis, to Orchard Therapeutics Ltd. (London, U.K.).
Orchard Gains GSK’S Rare Disease Gene Therapy Portfolio Read More »
Britain’s Orchard Therapeutics, which has already raised more than $140 million to fund its work in gene therapy, plans another private sale of shares following its acquisition of a portfolio of GlaxoSmithKline…
UK gene therapy firm Orchard plans stock offer after GSK deal Read More »
Collaborating with the German family-controlled drug maker on OSE’s novel checkpoint inhibitor aligns with French firm’s strategy of partnering its portfolio candidates.
OSE Immunotherapeutics Adds Boehringer Ingelheim To Its Pharma Partnering List Read More »
The Enterprisers: Life Science Leadership In Action. What good can come of setback? What is the value, if any, in so-called failure? Must a “failed” clinical trial wind up in the great waste bin of misbegotten science?
Reata Pharmaceuticals: Return & Reach Beyond Read More »
Boehringer Ingelheim and OSE Immunotherapeutics are partnering to develop the latter’s checkpoint inhibitor, OSE-172, for the treatment of advanced solid tumors.
Boehringer, OSE tie up in I-O deal that could total more than $1.4B Read More »
RNAi Therapy Components Are Surviving Degradation, Staying Potent, and Reaching More Targets Than Ever
RNAi Therapeutics: To the Liver … and Beyond Read More »
